Merck announced this week a brand new capsule to deal with COVID-19 and its software for Emergency Use Authorization, which Johns Hopkins School of Public Health Dr. Amesh Adalja predicted might come to market by the tip of 2021.

“If everything works according to plan, meaning the emergency use authorization, robust phase three clinical data and all of the signals look good,” he instructed “Fox News Live” on Sunday. “I think this is something hopefully by the end of the year we might see on shelves or be able to be prescribing to patients. And it would be game-changing.”

Dr. Adalja, a Merck advisory board member, defined that this remedy has been within the works “for some time” and is now displaying promising outcomes. The capsule will primarily deal with sufferers who expertise breakthrough infections, or for the unvaccinated, as a way to maintain folks out of the hospital.


Once the capsule is ingested, Adalja defined, its perform is to forestall the coronavirus from replicating and finishing its life cycle. The physician likened the drug to Tamiflu which is taken for a number of consecutive days.

Eric Shawn: Get ready to pop a COVID pillVideo

Even Dr. Anthony Fauci gave his public seal of approval on CNN’s “State of the Union,” calling the outcomes “quite impressive,” however Adalja pressed that the remedy continues to be not an alternative choice to the vaccine.

“Prevention is always better than treatment,” he stated. “It’s great that we’ve got treatments now but prevention is always going to be the priority, especially with safe and effective vaccines like we have in this country.”

Adalja stated that Pfizer additionally has a COVID-19 remedy drug on the way in which which is able to hopefully start to construct an antiviral “portfolio” in drugs.


“This is part of making COVID something that we can treat like other respiratory infections, day in and day out,” he stated. “We’re looking to a better future with a much more manageable COVID-19.”